Datasets

Title	RNA m6A-Ythdf1 in dendritic cells triggers anti-tumor immunity (MeRIP-Seq, RIP-Seq and Ribo-Seq in Flt3L-DCs)
Organism
Number of Samples	8
Release Date	2018/10/29 00:00
Sequencing Types
Protocol Details

Title
Authors	Han D,Liu J,Chen C,Dong L,Liu Y,Chang R,Huang X,Liu Y,Wang J,Dougherty U,Bissonnette MB,Shen B,Weichselbaum RR,Xu MM,He C
Journal	Nature
Publication Date	2019 Feb
Abstract	There is growing evidence that tumour neoantigens have important roles in generating spontaneous antitumour immune responses and predicting clinical responses to immunotherapies 1,2 . Despite the presence of numerous neoantigens in patients, complete tumour elimination is rare, owing to failures in mounting a sufficient and lasting antitumour immune response 3,4 . Here we show that durable neoantigen-specific immunity is regulated by mRNA N 6 -methyadenosine (m 6 A) methylation through the m 6 A-binding protein YTHDF1 5 . In contrast to wild-type mice, Ythdf1-deficient mice show an elevated antigen-specific CD8 + T cell antitumour response. Loss of YTHDF1 in classical dendritic cells enhanced the cross-presentation of tumour antigens and the cross-priming of CD8 + T cells in vivo. Mechanistically, transcripts encoding lysosomal proteases are marked by m 6 A and recognized by YTHDF1. Binding of YTHDF1 to these transcripts increases the translation of lysosomal cathepsins in dendritic cells, and inhibition of cathepsins markedly enhances cross-presentation of wild-type dendritic cells. Furthermore, the therapeutic efficacy of PD-L1 checkpoint blockade is enhanced in Ythdf1 -/- mice, implicating YTHDF1 as a potential therapeutic target in anticancer immunotherapy.
PMC	PMC6522227
PMID	30728504
DOI

Han et al. 2019 (PRJNA499089)